PROTAC Shows Efficacy Against Castration-Resistant Prostate Cancer in Preclinical Studies April 5, 2017 An orally bioavailable androgen receptor PROTAC, developed using a protein degradation technology, was effective in lowering tumor burden in mice bearing human castration-resistant prostate cancer, according to data presented at the AACR Annual Meeting 2017.Read more.Source: Medical Xpress Prostate Cancer News
An orally bioavailable androgen receptor PROTAC, developed using a protein degradation technology, was effective in lowering tumor burden in mice bearing human castration-resistant prostate cancer, according to data presented at the AACR Annual Meeting 2017.Read more.Source: Medical Xpress
Complete the Survey
